Arrowstreet Capital
RCEL icon

Arrowstreet Capital’s Avita Medical RCEL Stock Holding History

Arrowstreet Capital’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
+60,746
New +$262K ﹤0.01% 1828

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital's RCEL Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Avita Medical (RCEL) in Q2 2026: 60,746 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #1828 among its holdings.

73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Arrowstreet Capital held 60,746 shares of Avita Medical worth $251K as of Q2 2026.
  • Avita Medical was a new Arrowstreet Capital position in Q2 2026.
  • Avita Medical made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1828 holding.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.